Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2864 - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)


28 Sep 2019


Poster Display session 1


Tumour Site

Oesophageal Cancer


Seoyoung Lee


Annals of Oncology (2019) 30 (suppl_5): v747-v755. 10.1093/annonc/mdz266


S. Lee1, B.C. AHN1, S.Y. Park2, D.J. Kim2, C.G. Lee3, J. Cho3, J.H. Kim4, H.R. Kim5, Y. Kim5, S.R. Park6, Y.J. Chun1, M.H. Hong1, H.R. Kim1, B. Cho1

Author affiliations

  • 1 Division Of Medical Oncology, Yonsei Cancer Center Yonsei University, 6273 - Seoul/KR
  • 2 Department Of Thoracic And Cardiovascular Surgery, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 3 Department Of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 4 Department Of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 - Seoul/KR
  • 5 Department Of Thoracic And Cardiovasular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 6 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2864


Even though preoperative chemoradiotherapy (CRT) showed survival improvement in patients with resectable ESCC in a randomized trial over upfront surgery, ESCC still has a dismal prognosis. With the potential benefit of combining PD-1 blockade to CRT, we conducted a phase II trial which assessed the efficacy, feasibility, and safety of the combination of preoperative CRT and pembrolizumab (PEM) in ESCC (NCT02844075).


Patients (pts) with histologically confirmed ESCC (clinical stage Ib to III according to the American Joint Committee on Cancer 7th staging system) were enrolled. Pts received concurrent neoadjuvant chemotherapy (weekly paclitaxel and carboplatin), radiotherapy (44.1 Gy in 21 fractions), and PEM (every 3 weeks, 200 mg) during 5 weeks followed by surgery. After surgery, pts were treated with PEM during 2 years or until progression, unacceptable toxicity, death, or pts’ refusal, which came first. The primary endpoint was pathologic complete response (pCR) rate in the primary tumor and secondary endpoints were overall survival (OS), disease-free survival (DFS), the incidence of adverse events, and etc.


In a total of 28 enrolled pts (median age 60), 26 pts received esophagectomy. Two pts did not undergo surgery due to death (hematemesis) and consent withdrawal. There were two in-hospital mortality cases after surgery due to acute lung injury and four mortality cases due to disease progression. The pCR in primary tumor was achieved in 46.1% of pts who underwent resection (95% CI: 28.8 – 64.6). With a median follow-up of 12.4 months, median OS was not reached. Six, 12, and 18-month OS rates were 89.3%, 80.8%, and 73.1% respectively. There was a trend toward better DFS in the pCR group (n = 12) compared with the non-pCR group (n = 14) (HR = 0.33, p = 0.1). Most common treatment-related adverse events were neutropenia (50.0%) and liver enzyme elevation (30.8%) in the neoadjuvant and adjuvant period, respectively.


The addition of PEM to preoperative CRT in ESCC demonstrated promising efficacy with acceptable toxicity. Based on the results, further investigation is warranted in a phase III clinical trial. The exploratory endpoints including biomarkers analyses are ongoing.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.